FDA Expands Approval of Chemo-Free Bladder Cancer Combo in Curative Setting

The FDA approved pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa (Keytruda Qlex) in combination with enfortumab vedotin (Padcev) as perioperative treatment for adults with muscle-invasive bladder cancer. The approval expands the use of a chemo-free therapy in a curative setting for this condition.